Imunon, Inc. (NASDAQ: IMNN) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management [Yahoo! Finance]
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
IMUNON to Host R&D Day on September 18th